Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
Overview
To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: September 2007
Interventions
- Drug: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
- 1 drop in eye(s) every evening
Arms, Groups and Cohorts
- 1
- bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%
Clinical Trial Outcome Measures
Primary Measures
- Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year
- Time Frame: Baseline, 1 Year
- Change from baseline in bilateral (both eyes) IOP at the 1 year follow-up visit. IOP is a measure of the fluid pressure inside the eye. The bilateral IOP was calculated as an average between both eye’s IOP. A negative number change from baseline indicates reduction in IOP (improvement).
Participating in This Clinical Trial
Inclusion Criteria
- A diagnosis of Primary Open-Angle Glaucoma or Ocular Hypertension newly diagnosed OR presenting with insufficiently controlled IOP on current medication (in the opinion of the treating physician) – Patient is having both eyes treated Exclusion Criteria:
- Contraindications per product labelling will apply. – Patients with any ophthalmic co-morbidity with an influence on visual field deterioration or optic nerve head damage.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Allergan
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Medical Director, Study Director, Allergan
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.